Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria

J. A. Grant, D. I. Bernstein, C. E. Buckley, T. Chu, R. W. Fox, R. E. Rocklin, W. F. Schoenwetter, S. L. Spector, C. T. Stafford, J. E. Stroh, K. M. Karpenter

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The efficacy of terfenadine, a nonsedating H1 antihistamine, in the management of chronic idiopathic urticaria was compared with chlorpheniramine and placebo in a parallel multicenter trial. Subjects with symptoms of hives for 3 days per week for at least 6 weeks were initially screened and admitted if no identifiable cause for symptoms could be determined. Patients entered a single-blind placebo period, and if hives of moderate severity were present for at least 3 days during the week, they were randomly assigned in a double blind fashion to take terfenadine, 60 mg twice daily, chlorpheniramine, 4 mg three times a day, or placebo for 6 weeks. Data were analyzed for 122 patients. Those patients receiving both active treatments noted significant improvement in symptoms: pruritus, redness, number of hives, and waking hours during which hives were present, at the end of the first day of therapy. Symptom control by terfenadine was statistically superior to placebo during all 6 weeks, as rated by both patients and investigators. However, statistical significance was not achieved for chlorpheniramine at all observation points. Diphenhydramine was permitted as a relief medication for refractory symptoms and was taken by 52% of subjects receiving placebo, 26% taking chlorpheniramine, and only 9% of patients who were receiving terfenadine. In addition to providing superior symptom control, terfenadine caused less drowsiness and fatigue than chlorpheniramine. Terfenadine is a useful therapeutic agent for primary management of chronic idiopathic urticaria.

Original languageEnglish (US)
Pages (from-to)574-579
Number of pages6
JournalJournal of Allergy and Clinical Immunology
Volume81
Issue number3
StatePublished - 1988

Fingerprint

Terfenadine
Chlorpheniramine
Urticaria
Placebos
Therapeutics
Diphenhydramine
Sleep Stages
Histamine Antagonists
Pruritus
Multicenter Studies
Fatigue
Research Personnel
Observation

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Grant, J. A., Bernstein, D. I., Buckley, C. E., Chu, T., Fox, R. W., Rocklin, R. E., ... Karpenter, K. M. (1988). Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology, 81(3), 574-579.

Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. / Grant, J. A.; Bernstein, D. I.; Buckley, C. E.; Chu, T.; Fox, R. W.; Rocklin, R. E.; Schoenwetter, W. F.; Spector, S. L.; Stafford, C. T.; Stroh, J. E.; Karpenter, K. M.

In: Journal of Allergy and Clinical Immunology, Vol. 81, No. 3, 1988, p. 574-579.

Research output: Contribution to journalArticle

Grant, JA, Bernstein, DI, Buckley, CE, Chu, T, Fox, RW, Rocklin, RE, Schoenwetter, WF, Spector, SL, Stafford, CT, Stroh, JE & Karpenter, KM 1988, 'Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria', Journal of Allergy and Clinical Immunology, vol. 81, no. 3, pp. 574-579.
Grant, J. A. ; Bernstein, D. I. ; Buckley, C. E. ; Chu, T. ; Fox, R. W. ; Rocklin, R. E. ; Schoenwetter, W. F. ; Spector, S. L. ; Stafford, C. T. ; Stroh, J. E. ; Karpenter, K. M. / Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. In: Journal of Allergy and Clinical Immunology. 1988 ; Vol. 81, No. 3. pp. 574-579.
@article{753c0fed0db848e28d0e5d3652b0dc0d,
title = "Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria",
abstract = "The efficacy of terfenadine, a nonsedating H1 antihistamine, in the management of chronic idiopathic urticaria was compared with chlorpheniramine and placebo in a parallel multicenter trial. Subjects with symptoms of hives for 3 days per week for at least 6 weeks were initially screened and admitted if no identifiable cause for symptoms could be determined. Patients entered a single-blind placebo period, and if hives of moderate severity were present for at least 3 days during the week, they were randomly assigned in a double blind fashion to take terfenadine, 60 mg twice daily, chlorpheniramine, 4 mg three times a day, or placebo for 6 weeks. Data were analyzed for 122 patients. Those patients receiving both active treatments noted significant improvement in symptoms: pruritus, redness, number of hives, and waking hours during which hives were present, at the end of the first day of therapy. Symptom control by terfenadine was statistically superior to placebo during all 6 weeks, as rated by both patients and investigators. However, statistical significance was not achieved for chlorpheniramine at all observation points. Diphenhydramine was permitted as a relief medication for refractory symptoms and was taken by 52{\%} of subjects receiving placebo, 26{\%} taking chlorpheniramine, and only 9{\%} of patients who were receiving terfenadine. In addition to providing superior symptom control, terfenadine caused less drowsiness and fatigue than chlorpheniramine. Terfenadine is a useful therapeutic agent for primary management of chronic idiopathic urticaria.",
author = "Grant, {J. A.} and Bernstein, {D. I.} and Buckley, {C. E.} and T. Chu and Fox, {R. W.} and Rocklin, {R. E.} and Schoenwetter, {W. F.} and Spector, {S. L.} and Stafford, {C. T.} and Stroh, {J. E.} and Karpenter, {K. M.}",
year = "1988",
language = "English (US)",
volume = "81",
pages = "574--579",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria

AU - Grant, J. A.

AU - Bernstein, D. I.

AU - Buckley, C. E.

AU - Chu, T.

AU - Fox, R. W.

AU - Rocklin, R. E.

AU - Schoenwetter, W. F.

AU - Spector, S. L.

AU - Stafford, C. T.

AU - Stroh, J. E.

AU - Karpenter, K. M.

PY - 1988

Y1 - 1988

N2 - The efficacy of terfenadine, a nonsedating H1 antihistamine, in the management of chronic idiopathic urticaria was compared with chlorpheniramine and placebo in a parallel multicenter trial. Subjects with symptoms of hives for 3 days per week for at least 6 weeks were initially screened and admitted if no identifiable cause for symptoms could be determined. Patients entered a single-blind placebo period, and if hives of moderate severity were present for at least 3 days during the week, they were randomly assigned in a double blind fashion to take terfenadine, 60 mg twice daily, chlorpheniramine, 4 mg three times a day, or placebo for 6 weeks. Data were analyzed for 122 patients. Those patients receiving both active treatments noted significant improvement in symptoms: pruritus, redness, number of hives, and waking hours during which hives were present, at the end of the first day of therapy. Symptom control by terfenadine was statistically superior to placebo during all 6 weeks, as rated by both patients and investigators. However, statistical significance was not achieved for chlorpheniramine at all observation points. Diphenhydramine was permitted as a relief medication for refractory symptoms and was taken by 52% of subjects receiving placebo, 26% taking chlorpheniramine, and only 9% of patients who were receiving terfenadine. In addition to providing superior symptom control, terfenadine caused less drowsiness and fatigue than chlorpheniramine. Terfenadine is a useful therapeutic agent for primary management of chronic idiopathic urticaria.

AB - The efficacy of terfenadine, a nonsedating H1 antihistamine, in the management of chronic idiopathic urticaria was compared with chlorpheniramine and placebo in a parallel multicenter trial. Subjects with symptoms of hives for 3 days per week for at least 6 weeks were initially screened and admitted if no identifiable cause for symptoms could be determined. Patients entered a single-blind placebo period, and if hives of moderate severity were present for at least 3 days during the week, they were randomly assigned in a double blind fashion to take terfenadine, 60 mg twice daily, chlorpheniramine, 4 mg three times a day, or placebo for 6 weeks. Data were analyzed for 122 patients. Those patients receiving both active treatments noted significant improvement in symptoms: pruritus, redness, number of hives, and waking hours during which hives were present, at the end of the first day of therapy. Symptom control by terfenadine was statistically superior to placebo during all 6 weeks, as rated by both patients and investigators. However, statistical significance was not achieved for chlorpheniramine at all observation points. Diphenhydramine was permitted as a relief medication for refractory symptoms and was taken by 52% of subjects receiving placebo, 26% taking chlorpheniramine, and only 9% of patients who were receiving terfenadine. In addition to providing superior symptom control, terfenadine caused less drowsiness and fatigue than chlorpheniramine. Terfenadine is a useful therapeutic agent for primary management of chronic idiopathic urticaria.

UR - http://www.scopus.com/inward/record.url?scp=0023840315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023840315&partnerID=8YFLogxK

M3 - Article

C2 - 3126220

AN - SCOPUS:0023840315

VL - 81

SP - 574

EP - 579

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -